Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Pacira BioSciences is a specialty pharmaceutical company focused on non-opioid pain management, with its flagship product EXPAREL (liposomal bupivacaine) generating the majority of revenue through hospital and surgical center channels. The company operates in the post-surgical and acute care pain management market, competing against traditional opioids and other regional anesthetics. Stock performance is driven by EXPAREL volume growth in surgical procedures, pipeline development (iovera° cryoanalgesia system), and the company's ability to expand into new surgical indications while managing operating expenses toward profitability.
Pacira generates revenue by selling EXPAREL directly to hospitals and surgical centers at premium pricing ($285-$315 per vial) compared to generic bupivacaine, justified by extended pain relief (up to 72 hours) and opioid-sparing benefits. The company employs a specialized sales force targeting anesthesiologists, surgeons, and hospital pharmacy committees. Gross margins of 75.7% reflect the specialty pharmaceutical pricing model, though current negative operating margins (-10.5%) indicate the company is investing heavily in commercial expansion and pipeline development. Pricing power stems from clinical differentiation in reducing opioid consumption and hospital length-of-stay, though faces pressure from generic competition and hospital formulary scrutiny.
EXPAREL volume growth and penetration rates in key surgical procedures (orthopedic, colorectal, cesarean sections) - quarterly vial shipments and procedure adoption metrics
Pipeline development milestones for EXPAREL label expansions (nerve block indications) and new formulations, including FDA regulatory decisions
Competitive dynamics with generic liposomal bupivacaine entrants and pricing pressure from hospital group purchasing organizations (GPOs)
Operating margin trajectory and path to sustained profitability - quarterly EBITDA performance and operating expense management
Healthcare utilization trends affecting elective surgical volumes, particularly in ambulatory surgical centers where EXPAREL has higher penetration
Generic competition for liposomal bupivacaine - multiple companies have filed ANDAs (Abbreviated New Drug Applications) seeking FDA approval for generic EXPAREL equivalents, which could significantly erode pricing and market share post-2027 when key patents expire
Healthcare reimbursement pressure - CMS and private payers increasingly scrutinize high-cost pharmaceuticals, and failure to demonstrate cost-effectiveness (reduced hospital stays, lower opioid-related complications) could limit adoption or force price concessions
Opioid crisis policy shifts - while current regulatory environment favors non-opioid alternatives, any future policy changes or clinical guideline updates could affect EXPAREL's competitive positioning
Established pain management alternatives including continuous peripheral nerve blocks, multimodal analgesia protocols using generic drugs, and competing long-acting local anesthetics from companies like Heron Therapeutics (HTX-011)
Hospital formulary decisions increasingly driven by value-based purchasing and bundled payment models, where lower-cost generic bupivacaine may be preferred despite clinical benefits of EXPAREL
Negative operating margins (-10.5%) and net margins (-14.2%) create cash burn risk if revenue growth slows - current cash runway appears adequate with 5.26x current ratio and $200M operating cash flow, but sustained losses could pressure liquidity
Debt refinancing risk - with $200M+ in debt and negative earnings, refinancing at maturity could be costly if credit markets tighten or company performance deteriorates
moderate - Surgical volumes, particularly elective procedures in ambulatory surgical centers, exhibit moderate sensitivity to economic conditions. During recessions, patients may defer elective orthopedic and cosmetic procedures due to cost concerns or insurance coverage changes. However, emergency and urgent surgical procedures (trauma, cancer-related) remain relatively stable. The shift toward outpatient surgical settings (where EXPAREL has strong penetration) provides some insulation from acute care hospital budget pressures.
Rising interest rates have moderate impact through two channels: (1) higher borrowing costs on the company's $200M+ debt load, increasing interest expense and pressuring path to profitability, and (2) valuation multiple compression for unprofitable growth companies as investors demand higher returns. Lower rates benefit by reducing financing costs and making the stock more attractive on a discounted cash flow basis given negative near-term earnings.
Moderate credit exposure. While Pacira sells primarily to hospitals and surgical centers with generally strong credit profiles, tightening credit conditions can pressure hospital capital budgets and formulary decisions, potentially favoring lower-cost generic alternatives. The company's own debt/equity ratio of 0.58 is manageable but requires monitoring if operating losses persist. Widening credit spreads could increase refinancing costs when debt matures.
growth - The stock attracts growth investors focused on specialty pharmaceutical companies with differentiated products addressing large markets (post-surgical pain management). Despite current unprofitability, the 75.7% gross margin and 18.3% FCF yield appeal to investors betting on operating leverage as the company scales. However, negative earnings growth (-337%) and declining stock performance (-14% over 1 year) have likely shifted the investor base toward value-oriented buyers seeking turnaround potential at 1.4x sales and 8.5x EV/EBITDA.
high - As a small-cap ($1.0B market cap) specialty pharmaceutical company with single-product concentration, binary clinical/regulatory events, and negative profitability, PCRX exhibits high volatility. Stock moves are amplified by quarterly earnings surprises, FDA decisions on label expansions or generic approvals, and shifts in healthcare policy. The -6.8% three-month return amid broader market stability suggests company-specific volatility drivers.
